首页/数据集/Dataset from Phase 2, Observer Blinded, Controlled, Randomized Multi-Center Study in Adolescents and Young Adults to Evaluate Safety and Immunogenicity of Two Different rMenB With OMV + MenACWY Combination Vaccination Formulations

Dataset from Phase 2, Observer Blinded, Controlled, Randomized Multi-Center Study in Adolescents and Young Adults to Evaluate Safety and Immunogenicity of Two Different rMenB With OMV + MenACWY Combination Vaccination Formulations

NIAID Data Ecosystem2026-05-02 收录

疫苗临床试验

脑膜炎球菌联合疫苗评估

数据链接：

https://doi.org/10.25934/PR00010347 数据链接链接失效反馈

官方服务：

资源简介：

This study will evaluate the safety and immunogenicity of combination vaccines as compared to the reference vaccines

应用场景：

创建时间：

2025-02-10

疫苗临床试验

免疫反应

Background: Novel tuberculosis vaccines should be safe, immunogenic, and effective in various population groups, including HIV-infected individuals. In this phase II multi-centre, double-blind, placeb

DataONE2014-12-22 更新160

ATN 064 Burk HPV DNA Dataset in Immunogenicity, Safety, Tolerability, and Behavioral Consequences of an HPV-6, -11, -16, -18 Vaccine in HIV-Infected Young Women

疫苗临床试验

HIV感染者免疫干预

Burk Lab HPV DNA data Study Description A Phase II, open-label, multi-center study that evaluated the immunogenicity, safety, tolerability, and behavioral impact of an HPV-6, -11, -16, -18 vaccine in

NIAID Data Ecosystem40

Dataset from Safety and Immunogenicity Study of GSK Biologicals' Candidate Tuberculosis Vaccine (692342) When Administered to Healthy Infants

疫苗临床试验

结核病预防

This purpose of the study is to assess the safety and immunogenicity of a GSK Biologicals' candidate tuberculosis vaccine (692342) when administered concomitantly with or after the Expanded Programme

NIAID Data Ecosystem20

DataSheet_1_Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial.docx

癌症免疫治疗

疫苗临床试验

BackgroundImmune checkpoint blockade with monoclonal antibodies targeting programmed death 1 (PD-1) and its ligand PD-L1 has played a major role in the rise of cancer immune therapy. We have identifie

NIAID Data Ecosystem70

Characteristics of HVTN 502 and 503 trial participants.

疫苗临床试验

免疫基因型分析

Data shown are median values (interquartile range) unless otherwise indicated. * At time of sampling § HLA-B*27, B51, B*5701/03, B*5801 and B*8101 Characteristics of HVTN 502 and 503 trial participant

NIAID Data Ecosystem20

Dataset from Phase 2, Observer Blinded, Controlled, Randomized Multi-Center Study in Adolescents and Young Adults to Evaluate Safety and Immunogenicity of Two Different rMenB With OMV + MenACWY Combination Vaccination Formulations

资源简介：

相关数据集